Eli Lilly replaces corporate director

Top ten pharmaceutical firm Eli Lilly, which produces the world’s best selling anti-depressant, Prozac, has promoted Stephen Whitehead to the position of corporate affairs director for Europe.

Top ten pharmaceutical firm Eli Lilly, which produces the world’s

best selling anti-depressant, Prozac, has promoted Stephen Whitehead to

the position of corporate affairs director for Europe.



He replaces Klaus Welzel, who has been appointed business development

director for Europe.



Based at the firm’s London office, Whitehead will lead a team of five

people, reporting to European president Bert van den Bergh.



Whitehead, who was previously Eli Lilly UK corporate affairs director,

joined the company in January 1998 from Grand Metropolitan, where he was

external affairs director for three years.



Part of his task is to persuade governments to meet the costs of

innovative new medicines - several, including the UK government, are

alarmed by the rising costs of new drugs, such as Viagra.



Whitehead’s brief is to ensure best practice is maintained for Eli Lilly

corporate affairs across Europe. It includes product communications and

also some internal communications.



He will establish a corporate affairs best practice network within the

company across Europe.



Whitehead will work closely with the agencies retained by Eli Lilly,

which include Cohn and Wolfe and Edelman PR Worldwide, who both handle

PR for prescription medicines.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in